CRTX News and Press, Cortexyme Inc. From 12/11/20

Cortexyme, Inc. (CRTX) is down -19.4% as Citi initiated coverage on the stock with a ‘Sell’ rating. Noting that risks from ‘company’s “unique” Alzheimer’s disease approach are still not reflected in the stock even after the recen...

Gainers: China HGS Real Estate (HGSH) +136%.Pioneer Power Solutions (PPSI) +54%.Star Peak Energy Transition (STPK) +45%.Fangdd Network Group (DUO) +41%.Sutro Biopharma (STRO) +35%.Collective Growth (CGROU) +34%.CIIG Merger (CIIC) +31%.Collective Growth (CGRO) +27%.AquaBounty Technologies...

China HGS Real Estate (HGSH) +164%.Hexindai (HX) +32%.Sutro Biopharma (STRO) +25% as ovarian cancer drug study offers encouraging interim data.Domo (DOMO) +23% on Q3 results.CIIG Merger (CIIC) +22%.Sigma Labs (SGLB) +20%.Collective Growth Corporation (CGRO) +18%.Foresight Autonomous...

Cortexyme (CRTX) announces that, following an interim analysis by the independent Data Monitoring Committee ((DMC)) at the year 1 time point, the Phase 2/3 clinical trial, GAIN, evaluating lead candidate atuzaginstat (COR388) in patients with mild-to-moderate Alzheimer's disease ((AD)) w...

-- GAIN Trial passes futility analysis and will continue to 1-year endpoint following the independent Data Monitoring Committee recommendation; topline results expected on time in December 2021 -- -- Final study enrollment remains at 643; no sample size adjustment -- -...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. A ho...

Cortexyme (CRTX): Q3 GAAP EPS of -$0.73.Cash, cash equivalents and short term investments of $137.8MPress Release For further details see: Cortexyme reports Q3 results

— GAIN Trial enrollment complete with 643 participants — GAIN Trial interim analysis on schedule to complete in December 2020 Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering potential therapeutics for Alzheimer ...

-- Data demonstrate that patients enrolled in the GAIN Trial have baseline biomarkers consistent with Alzheimer’s disease and potential responders to atuzaginstat -- -- Press release issued in advance of CTAD presentation as an SEC exemption to the embargo policy, grant...

-- Oral presentation at Clinical Trials on Alzheimer's Disease 2020 will include baseline characteristics of the Phase 2/3 GAIN Trial ahead of planned interim analysis expected to occur before year-end 2020 -- -- Poster at Society for Immunotherapy of Cancer Annual Meeting eva...